These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33355084)

  • 1. Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case report.
    Hibino H; Makino Y; Sakiyama N; Makihara-Ando R; Hashimoto H; Akiyoshi T; Imaoka A; Fujiwara Y; Ohe Y; Yamaguchi M; Ohtani H
    Int J Clin Pharmacol Ther; 2021 Apr; 59(4):328-332. PubMed ID: 33355084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
    Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
    Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
    Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
    Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
    Ando Y; Hayashi T; Ito K; Suzuki E; Mine N; Miyamoto A; Oya M; Matsuda H; Isaji A; Nakanishi T; Imaizumi K; Shibata T; Okada T; Sakurai K; Naito K; Uyama I; Kawada K; Takahashi H; Yamada S
    Support Care Cancer; 2016 Feb; 24(2):871-878. PubMed ID: 26206077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
    de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
    Uchino J; Hirano R; Tashiro N; Yoshida Y; Ushijima S; Matsumoto T; Ohta K; Nakatomi K; Takayama K; Fujita M; Nakanishi Y; Watanabe K
    Asian Pac J Cancer Prev; 2012; 13(8):4187-90. PubMed ID: 23098425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F
    Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience with aprepitant in the prevention of nausea and vomiting caused by highly emetic chemotherapy of lung cancer].
    Tamási L; Müller V; Magyar P
    Magy Onkol; 2008 Jun; 52(2):179-83. PubMed ID: 18640894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
    Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
    Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
    Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
    Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
    Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.